剥离层:在多发性骨髓瘤中支持性干细胞增加后,Talquetamab复发性皮肤毒性
Alexander D Heini1, Vera Ulrike Bacher2, Dilara Akhoundova3
1Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland, alex@heini.be.
Acta haematologica
|March 6, 2024
概括
多发性骨髓瘤的双特异性抗体talquetamab可以引起皮肤毒性. 在CAR-T治疗后进行干细胞增活后,一名患者出现了严重的皮肤反应,这凸显了需要谨慎管理的必要性.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 双特异性抗体,如talquetamab,正在推进多发性骨髓瘤治疗.
- 塔尔基塔马布针对骨髓瘤细胞的GPRC5D,也针对质化组织,导致潜在的皮肤毒性.
- 管理毒性对于优化新疗法患者的治疗结果至关重要.
研究的目的:
- 报告一个严重的talquetamab介导的皮肤毒性病例.
- 在复发多发性骨髓瘤患者中研究talquetamab和造血干细胞增强之间的相互作用.
- 突出综合免疫疗法和干细胞干预的患者管理不良事件的复杂性.
主要方法:
- 一个多发性骨髓瘤患者的病例报告,在CAR-T治疗后接受了talquetamab治疗.
- 在血造干细胞促进细胞衰竭后观察皮肤毒性.
- 临床评估和不良事件的管理.
主要成果:
- 患者在接受血液造血干细胞增强后经历了talquetamab诱导的严重皮肤毒性复发.
- 这种恶化发生在CAR-T治疗后持续性细胞衰竭管理的背景下.
- 该案例表明,这些治疗方式之间存在显著的不良事件相互作用.
结论:
- 这一案例凸显了talquetamab免疫疗法与多发性髓瘤干细胞干预之间的复杂相互作用.
- 严重的皮肤毒性可能会被支持性干细胞疗法加剧.
- 个性化管理策略对于减轻不良影响和最大限度地提高治疗效益至关重要.
更多相关视频
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
21.4K
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
相关概念视频
Stem Cell Therapy for Tissue Regeneration
4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Bone Marrow Sampling and Transplants
330
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
330
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
